Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)

Introduction The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has led to a change in the clinical management of breast cancer. Nausea and vomiting are the most common adverse events of T-DXd, which cannot be completely alleviated by standard prophylactic regimens. Olanzapine is particularl...

Full description

Bibliographic Details
Main Authors: Shigeto Maeda, Yasutaka Chiba, Koji Matsumoto, Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Kenichi Watanabe, Takamichi Yokoe, Chiyo K Imamura, Tsutomu Iwasa, Daisuke Takiguchi, Toshimi Takano
Format: Article
Language:English
Published: BMJ Publishing Group 2023-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/4/e070304.full

Internet

https://bmjopen.bmj.com/content/13/4/e070304.full

Similar Items